A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
暂无分享,去创建一个
G. Giaccone | S. Steinberg | E. Szabo | D. Schrump | J. Trepel | C. Redon | W. Figg | C. Peer | Y. Tomita | Min-Jung Lee | R. Piekarz | Anish Thomas | A. Rajan | C. Carter | A. López-Chávez | Yuanbin Chen | B. Scepura | Ari Frosch | B. Scepura
[1] Kunihiko Kobayashi,et al. Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803. , 2013 .
[2] Y. Hasegawa,et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. , 2013, Cancer research.
[3] G. Giaccone,et al. Characterization and Management of Cardiac Involvement of Thymic Epithelial Tumors , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] B. Goh,et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Pili,et al. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy , 2012, Oncoimmunology.
[6] N. L. La Thangue,et al. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications , 2012, Immunology and cell biology.
[7] Yi-Song Wang,et al. Thymic malignancies: from clinical management to targeted therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. D. de Bono,et al. Belinostat: clinical applications in solid tumors and lymphoma , 2011, Expert opinion on investigational drugs.
[9] C. D. Salcido,et al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer , 2011, Cell cycle.
[10] G. Giaccone,et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Dipersio,et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS) , 2011, Annals of Hematology.
[12] J. Plumb,et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101) , 2011, Cancer Chemotherapy and Pharmacology.
[13] William F. Blakely,et al. The Use of Gamma-H2AX as a Biodosimeter for Total-Body Radiation Exposure in Non-Human Primates , 2010, PloS one.
[14] J. Kirkwood,et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.
[15] Jenna M. Sullivan,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.
[16] J. Bono,et al. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours , 2010, British Journal of Cancer.
[17] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[18] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[19] Xin Wu,et al. HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells , 2008, PloS one.
[20] S. Suster,et al. Histologic classification of thymoma: the World Health Organization and beyond. , 2008, Hematology/oncology clinics of North America.
[21] Linda J. Kuo,et al. γ-H2AX - A Novel Biomarker for DNA Double-strand Breaks , 2008 .
[22] Robert Brown,et al. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.
[23] A. Cooke,et al. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. , 2008, Critical reviews in immunology.
[24] Linda J. Kuo,et al. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. , 2008, In vivo.
[25] E. Olson,et al. Deacetylase inhibition promotes the generation and function of regulatory T cells , 2007, Nature Medicine.
[26] K. Mori,et al. Multidisciplinary Treatment for Advanced Invasive Thymoma with Cisplatin, Doxorubicin, and Methylprednisolone , 2005, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] A. Gartel. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. , 2005, Leukemia research.
[28] A. Rosenwald,et al. Selective loss of regulatory T cells in thymomas , 2004, Annals of neurology.
[29] Edward S. Kim,et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. , 2004, Lung cancer.
[30] M. Jung,et al. Enhancement of Radiation Sensitivity of Human Squamous Carcinoma Cells by Histone Deacetylase Inhibitors , 2004, Radiation research.
[31] Yu-Chung Wu,et al. Managements of locally advanced unresectable thymic epithelial tumors. , 2004, Journal of the Chinese Medical Association : JCMA.
[32] K. Kondo,et al. Lymphogenous and hematogenous metastasis of thymic epithelial tumors. , 2003, The Annals of thoracic surgery.
[33] Y. Pommier,et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.
[34] R. Pfeiffer,et al. Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies , 2003, International journal of cancer.
[35] A. Marx,et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors , 2002, Cancer.
[36] W. Allan,et al. The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase IIα Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines1 , 2001 .
[37] P. Marks,et al. Inhibitors of histone deacetylase are potentially effective anticancer agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] W. Allan,et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. , 2001, Molecular cancer therapeutics.
[39] R. Livingston,et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] S. Mills,et al. Thymomas and thymic carcinomas. , 1990, Seminars in diagnostic pathology.
[41] A. Paccagnella,et al. Chemotherapy of invasive thymoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Y. Monden,et al. Follow‐up study of thymomas with special reference to their clinical stages , 1981, Cancer.